230 results about "Treg cell" patented technology

The invention relates to 2 '-fucosyllactose, in particular to application of the 2'-fucosyllactose to preparation of immune balance drugs or food. The immune balance comprises regulation and control of the ratio of Th17 cells to Treg cells of Th17 / Treg immune imbalance offspring activated by maternal immune or induced by virus infection; according to the application disclosed by the invention, the fact that filial generations generated after the maternal body of a mammal generates immune reaction activation can regulate and control the proportion of Th17 and Treg cells through the influence of 2 '-fucosyllactose on intestinal flora is found, so that Th17 and Treg immune balance is realized; in addition, social and cognitive disorders and repetitive behaviors related to filial generation autism induced by Th17 / Treg immune imbalance can be improved.

The invention discloses a pharmaceutical composition for promoting aTreg cell differentiation and application thereof, and relates to the field of biological medicine, and the pharmaceutical composition comprises zinc salt, a basic cell culture medium, fetal calf serum, antibiotic, L-glutamine and a pH buffer agent. According to the application, the basic cell culture medium is used for providing basic nutrition required by cell growth for lymphocytes, the fetal calf serum is used for providing growth factors, hormones, adhesion proteins and nutrient substances required by cell growth for the lymphocytes, and the antibiotics are used for preventing bacterial infection; l-glutamine provides key amino acid for cell energy metabolism and participates in synthesis of protein and nucleic acid, zinc salt provides zinc ions, and under the comprehensive action, the proportion of Treg cells and aTreg cells differentiated from lymphocytes in peripheral blood mononuclear cells is increased.

Methods and compositions for treating fibrosis (e.g., cardiac fibrosis), or other conditions associated with inflammation and / or fibrosis are provided. Methods can include administering a nucleic acid encoding a sialic acid-binding immunoglobulin-type lectin 9 (Siglec-9) protein to a subject in need of fibrosis treatment, where the Siglec-9 protein is expressed by the nucleic acid in regulatory T (Treg) cells in the subject. Methods and compositions can include Treg cells that overexpress Siglec-9 to enhance the ability of Treg cells to target cells expressing amine oxidase, copper containing 3 (AOC3), including fibroblasts or myofibroblasts. In some embodiments, the enhanced Treg cells are targeted to myofibroblasts (e.g., cardiac myofibroblasts) with elevated expression of fibrotic genes.

The invention relates to the technical field of biology, in particular to a Treg cell amplification culture medium and a preparation method of Treg cells. According to the method for in-vitro amplification of the regulatory T cells (Treg) from peripheral blood, the amplification efficiency and purity of the Treg cells are improved, the culture cost is reduced, the culture period is shortened, and the problem of trophoblast cell residues in subsequent clinical application is solved.

The invention belongs to the technical field of preparation of polypeptides, and particularly relates to a self-assembled polypeptide capable of responding to alkaline phosphatase and degrading Neuropilin-1 as well as a preparation method and application of the self-assembled polypeptide. The self-assembled polypeptide (formula I) provided by the invention has a self-assembly starting unit 'GNNQQNY (SEQ ID NO: 1)', can be self-assembled in vitro, and can form nanofibers after responding to alkaline phosphatase, so that not only can the critical self-assembly concentration of the polypeptide be reduced, but also the binding capacity with target protein can be improved. The material can degrade NRP1 on the surfaces of tumor cells and Treg cells, and has huge potential in promoting immunotherapy of tumors.

In some aspects, the present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising administering a KRAS inhibitor and a regulatory T cell (Treg)-depleting agent to the subject. In some aspects, the present disclosure is further directed to methods of reducing the number of Treg cells (Tregs) in a tumor environment (TME) in a subject who receives a therapy with a KRAS inhibitor comprising administering a Treg-depleting agent to the subject. In some aspects, the present disclosure is further directed to methods of treating a tumor in a subject who is identified as having an increased number of Tregs in a TME, or as having a spatial cellular community comprising Tregs in a TME.

A kit for detecting expression of AIRE and Treg in lymphatic tissue infected by EB virus comprises colloidal quantum well antibody conjugates, including a colloidal quantum well and protein AIRE and GITR conjugates and a colloidal quantum well and antibody CD25 and Foxp3 conjugates. The detection method comprises the following steps: (1) carrying out slicing treatment on a lymphatic tissue, and carrying out antigen repair by using an antigen repair liquid; (2) respectively adding colloidal quantum well proteins or antibodies coupled with different targets to dye the sections; (3) carrying out nucleus staining; and (4) collecting multi-channel fluorescence image information of the tissue slice, and judging expression levels and mutual relations of AIRE, Treg cells and dendritic cells in immune tolerance in combination with spatial positioning and intensity distribution of fluorescence signals of different channels. According to the invention, qualitative or quantitative multi-parameter and high-precision detection of the immune tolerance related cells in the lymph tissue is realized.

The present disclosure is directed to the combination of a Fas axis antagonist, such as an anti-FasL antibody, and a Treg cell depletion therapy, for example an anti-CD25 antibody, optionally with a cancer vaccine, for use in the treatment of cancer.

The present invention relates to methods of monitoring and efficacy assessment of cell therapy for patients treated with CD4 + Fox P3 + T regulatory cells. Further subject matter relates to methods of cell therapy using CD4 + Fox P3 + T regulatory cells and methods of monitoring of the invention.

Described herein are serum-free and feeder-free methods and compositions for the tunable differentiation and production of CD4+ (single positive) T cells and CD8+ (single positive) T cells, by adjusting T cell receptor (TCR) stimulation and notch activation (or notch signaling activation, stimulation or inducement). In some other aspects the invention provides a method and in vitro niche and cell culture media that results in enhancing CD4+ (SP) T cell generation, including naive mature CD4+ single positive T cells from double positive (DP) CD4+8+cells or CD8+(SP) T cells by TCR stimulation while having low or no notch signaling activation, stimulation or inducement. In yet other aspects, the invention provides a method, niche and culture media for producing cells derived from CD4+ (SP) T cells, including Treg cells.

The present invention provides a use of an Lck / Fyn-mediated STAT3 activation pathway as a target in the preparation or screening of a product. The product blocks the Lck / Fyn-mediated STAT3 activation pathway, inhibits differentiation of Th17 cells, and promotes transdifferentiation of the Th17 cells into Treg cells, thereby preventing or treating a Th17 cell-related immune disease. On the basis of the target, the present invention provides a use of an Lck / Fyn-mediated STAT3 activation blocker in the preparation of a product. The blocker is selected from an Lck / Fyn kinase inhibitor or a substance that specifically inhibits correct binding of Lck / Fyn and STAT3. The present invention provides a use of one or more biomaterials in the preparation of a product for preventing or treating the Th17 cell-related immune disease. The present invention also provides a drug for preventing or treating the Th17 cell-related immune disease and a treatment method thereof. Blocking Lck / Fyn-mediated STAT3 phosphorylation can be applied to the treatment of the Th17 cell-related immune disease or improvement of the capability to prevent an immune disease caused by the Th17 cells.

In some aspects, the present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising administering a KRAS inhibitor and a regulatory T cell (Treg)-depleting agent to the subject. In some aspects, the present disclosure is further directed to methods of reducing the number of Treg cells (Tregs) in a tumor environment (TME) in a subject who receives a therapy with a KRAS inhibitor comprising administering a Treg-depleting agent to the subject. In some aspects, the present disclosure is further directed to methods of treating a tumor in a subject who is identified as having an increased number of Tregs in a TME, or as having a spatial cellular community comprising Tregs in a TME.

The present invention relates to methods for carefully monitoring and evaluating the efficacy of cell therapy in patients treated with CD4+FoxP3+ regulatory T cells. Further subject matter relates to cell therapy methods using CD4+FoxP3+ regulatory T cells and the monitoring methods of the invention.

The invention relates to the technical field of primary local hyperhidrosis, in particular to a biomarker for detecting primary local hyperhidrosis and application of the biomarker, and the biomarker comprises but is not limited to one or more of the ratio of Th17 cells to Treg cells, IL-17A, IL-6, ROR gamma t and FoxP3. According to the invention, a multi-dimensional detection system covering PFH core pathological links (immune disorder, hyperactivity of sympathetic nerves and hyperfunction of sweat gland) is constructed by integrating immune related markers such as Th17 / Treg cell ratio, IL-17A, IL-6, ROR [gamma] t, FoxP3 and the like and combining the concentrations of peripheral blood epinephrine (E) and noradrenaline (NE) and the gene expression levels of sweat gland tissues AQP5 and Cacna1c. And a potential molecular target is provided for developing a novel therapeutic strategy (such as specific blocking of an IL-17 signal channel or enhancement of a Treg function) of a targeted Th17 / Treg axis.

The application of phlorizin in the medicine for treating and / or preventing lupus nephritis, the molecular formula of phlorizin is C 21 H 24 O 10 , the application promotes the differentiation of regulatory T cells (Treg) by applying phlorizin to up-regulate the PI3K / Akt signal pathway, thereby reducing the symptoms of lupus nephritis, and provides an effective treatment method with less side effects. In the application, the traditional Chinese medicine monomer phlorizin can effectively promote the differentiation of Treg cells, and compared with compound traditional Chinese medicine, the use of single component has more advantages in drug efficacy control and efficacy evaluation. In addition, phlorizin is widely sourced, low in cost and non-toxic, and is very suitable for long-term treatment of lupus nephritis.

The present application relates to interleukin-2 variants and methods of use thereof. The present invention relates to polypeptides that share a primary sequence with human IL-2 in addition to several mutated amino acids. A panel of IL-2 variants comprises mutations with profound impressive manufacturability that preferentially promote proliferation, survival, activation and / or function of immunosuppressive regulatory T cells (Treg: CD4 + CD25 + FoxP3 +) over effector T cells and NK cells. Also included is the therapeutic use of such IL-2 selective agents, alone or in combination with immunomodulators or disease tissue targeting antibodies, proteins or peptides, for the treatment of Treg cell deficiency, various autoimmune and inflammatory disorders, organ transplantation and graft versus host disease. In another aspect, the invention relates to pharmaceutical compositions comprising the disclosed polypeptides. Finally, the invention relates to the therapeutic use of the disclosed polypeptides and pharmaceutical compositions due to their selective modulation of the immune system on diseases such as autoimmune and inflammatory disorders.

The invention discloses an application of Notch2 overexpression lentivirus in promoting aTreg cell differentiation, and relates to the field of immune cell culture, and the application comprises the following steps: suspending PBMC in a T cell culture medium, laying a plate, adding Notch2 overexpression lentivirus, and culturing at 36.8-37.2 DEG C. The invention also discloses a preparation method of the Notch2 overexpression lentivirus. According to the application, the Notch2 overexpression lentivirus and the PBMC (peripheral blood mononuclear cell) are co-cultured on a culture medium, and the PBMC (peripheral blood mononuclear cell) is transfected by utilizing the Notch2 overexpression lentivirus, so that Notch2 protein molecules are overexpressed, and the number of Treg cells and aTreg cells in lymphocytes is increased.

The invention discloses an immunomodulatory composition based on a cordycepin-selenium nano chelate and a preparation method thereof, and belongs to the technical field of biological medicines.The immunomodulatory composition is characterized in that 15-25 nm zero-valent selenium nano particles are chelated through hydroxyl of cordycepin and N7 site bidentate coordination, and a stable five-membered ring structure with the molar ratio is formed; the preparation method comprises the following steps: reducing sodium selenite in an inert atmosphere to generate selenium colloid, chelating the selenium colloid with a cordycepin ethanol solution, and carrying out ultrafiltration and freeze-drying to obtain the product. The invention aims to solve the problems of fuzzy structure, inconsistent batch, uncontrollable immunomodulatory function and the like caused by non-specific mixing in the prior art, and the composition can bidirectionally regulate and control IRF3 pathways, promote polarization of M2 type macrophages and proliferation of Treg cells, and has a clear immunomodulatory mechanism and excellent stability.

Provided are a CCR8-targeting antibody or an antigen-binding fragment thereof, and an application thereof. The antibody targeting CCR8 or the antigen binding fragment of the antibody is specifically bound with CCR8. The invention further provides application of the antibody in blocking a signal channel for binding / inducing CCR1 and CCR8, clearing CCR8 positive Treg cells through ADCC action and enhancing anti-tumor immunity.

The present invention relates to methods for predicting and monitoring of the course of type 1 diabetes with the use of detection of fragments of preproinsulin from sera of the patients, specifically in patients treated with cell therapies with CD4+ Fox P3+ T regulatory cells (in the following Treg cells" or "Tregs"). The present invention relates also to the possibility of the use of the said fragments of preproinsulin in the treatment of patients with type 1 diabetes directly or as agents used during manufacturing of antigen-specific Tregs for the treatment of type 1 diabetes.

The present invention discloses a novel aporphine compound, its preparation method and applications, and its structural formula is shown as follows. The name of the novel aporphine compound is 2-methoxy-9-hydroxy-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline (III 11 ). In the present invention: ① By using the computer-aided drug design method in the forefront field of pharmacy, this compound is designed according to the binding requirements of the drug action target; ② This compound is synthesized from 3-methoxyphenethylamine and 2-bromo-5-hydroxybenzaldehyde, and its preparation method is simple; ③ This compound is an aryl hydrocarbon receptor (AhR) agonist and an inducer for the generation of regulatory T cells (Treg cells), and can be used for the prevention and treatment of immune inflammation and related diseases. ④ This compound shows good plasma protein binding rate and bioavailability, and has good prospects for drug development. #imgabs0#

This invention relates to a pharmaceutical composition for treating autoimmune diseases. The pharmaceutical composition for treating autoimmune diseases comprises an antibody and an inhibitor, wherein the antibody includes at least one of an OX40 antibody and an OX40L antibody, and the inhibitor includes at least one of a Janus kinase inhibitor and a RORγt inhibitor. In the above-mentioned pharmaceutical composition for treating autoimmune diseases, the Janus kinase inhibitor and / or the RORγt inhibitor can inhibit the secretion of IL17A by Treg cells induced by OX40 antibody and / or OX40L antibody, thereby reducing IL17A-promoted pathological inflammation and improving the efficacy of OX40 antibody and / or OX40L antibody in treating autoimmune diseases.

The invention relates to the field of cell therapy, in particular to a regulatory T cell targeting IL12RB1 and application of the regulatory T cell. The regulatory T cell provided by the invention comprises a P40 subunit or a mutant thereof. According to the invention, a natural protein sequence is used, so that the risk that the antigen has immunogenicity caused by scFv can be avoided; the Treg cells are homed to the inflammation part, and the activated lymphocytes are inhibited.

The invention relates to the technical field of biomedicine, in particular to an STA-5326-loaded heterozygous exosome oral preparation which comprises an STA-5326-loaded heterozygous exosome and an acid-resistant shell covering the surface of the heterozygous exosome, and the heterozygous exosome is at least fused with a Treg cell exosome and an MSCs cell exosome. Experiments show that the STA-5326-loaded hybrid exosome oral preparation has a good treatment effect on ulcerative colitis, can regulate the immune environment in a UC colon part, has good stability, and can be enriched in an inflammation area to repair an intestinal damaged barrier.

The invention relates to an application of a trichina succinic acid coenzyme A ligase beta-like protein SUCLA-beta. The invention identifies a trichina recombinant protein SUCLA-beta which can be used for preventing or treating colitis. A mouse colitis model is successfully copied, it is proved that the protein can improve intestinal inflammation caused by TNBS, the disease activity indexes of mice treated by the trichina recombinant protein SUCLA-beta in a treatment group or a prevention group are reduced, intestinal injury and inflammation are relieved, the disease activity indexes are gradually reduced along with dosage increase, and the intestinal injury and inflammation are relieved. Intestinal injury and inflammatory symptoms are gradually relieved, and the trichina recombinant protein SUCLA-beta can relieve inflammatory response by adjusting the proportion of Th1 / Th2 / Th17 / Treg cells. The trichina recombinant protein SUCLA-beta has a relatively good application prospect in the aspect of preventing or treating colitis.

A method of promoting T-cell function, comprising administering an effective amount of a compound of the present invention, including 2-hydroxybenzylamine, methyl-2-hydroxybenzylamine, or ethyl-2-hydroxybenzylamine; or a pharmaceutically acceptable salt thereof.

The present application relates to the medical technical field, especially to the application of FYB1 gene as a marker in preparation of gastric cancer diagnosis or prognosis judging reagent. The present application research finds that FYB1 gene is highly expressed in gastric cancer tissue and negatively correlated with the prognosis of patients, and can be used as a gastric cancer marker for gastric cancer detection and efficacy evaluation. In addition, FYB1 is positively correlated with the expression of Treg cell marker FOXP3 and co-localized in tissues, suggesting that FYB1 may promote gastric cancer tumor immune escape; the expression of FYB1 gene can significantly inhibit the proliferation, migration and invasion ability of gastric cancer cells, and inhibit tumor growth, indicating that FYB1 gene can be used as a gastric cancer treatment target and play an important role in the treatment of gastric cancer patients.

The invention belongs to the field of biological medicine, and discloses application of parabacteroides dieldrii in preparation of an osteoporosis improving agent. The research of the inventor finds that after the parabacteroides dieldrii is supplemented through intragastric administration, the proportion of Th17 cells can be reduced, secretion of IL-17 and TNF-alpha can be reduced, and the activity of osteoclasts can be inhibited; according to the present invention, with the application of the parabacteroides dieldrii in the preparation of the oral liquid, the osteoporosis can be effectively improved by adding the parabacteroides dieldrii in the stomach, the osteoporosis can be effectively improved, the osteoporosis can be effectively improved, and the great application prospect can be provided, and the effects of the oral liquid such as the intestinal tract, the intestinal tract flora structure, the probiotic (such as the bifidobacterium and the lactobacillus), and the osteoporosis can be effectively improved can be provided.

The present application relates to the technical field of biology, and discloses an anti-CCR8 antibody or an antigen binding fragment thereof, and a use thereof. The antibody can specifically bind to at least one epitope of CCR8, can also bind to Treg cells, has ADCC activity, and provides new possibilities for the treatment and / or prevention of cancer.

The invention discloses an anti-CD25 nano antibody or an antigen binding fragment thereof and application thereof, and relates to the technical field of biology. The anti-CD25 nano antibody or the antigen binding fragment thereof can be specifically bound with CD25, and can not block the binding of IL-2 and CD25, thereby being beneficial to reducing the number of Treg cells and enhancing the anti-tumor capability, and providing new possibility for the treatment and / or prevention of tumors.